Central pontine myelinolysis (CPM) and extrapontine myelinolysis (EPM) are dire neurological disorders, characterized by severe damage to the myelin sheath of neurons, which typically result from rapid correction or overcorrection of systemic hyponatremia. For many years, both conditions have been considered universally fatal, though survivors have been reported more recently. Pediatric cases are rare. We present a 13-year-old boy with panhypopituitarism secondary to repair of a nasofrontal encephalocele in infancy, managed on long-term corticosteroid, deamino arginine vasopressin and thyroid hormone. He presented with severe hyponatremia (116 mEq/l), which during correction rapidly and unexpectedly increased to 176 mEq/l, resulting in profoundly impaired consciousness. Brain imaging revealed multiple bilateral changes in the basal ganglia, thalamus, pons and cerebral white matter, consistent with both CPM and EPM. Malignant cerebellar edema necessitated emergent suboccipital craniectomy, with subsequent improvement in level of consciousness and imaging postoperatively. However, he succumbed to acute cardiorespiratory arrest 8 weeks later. Nine similar cases from the literature are reviewed.

Keywords:
Central pontine myelinolysis, Extrapontine myelinolysis, DDAVP, Hyponatremia
1.
Adams RD, Victor M, Mancall EL: Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients. AMA Arch Neurol Psychiatry 1959;81:154–172.
2.
Abbott R, Silber E, Felber J, Ekpo E: Osmotic demyelination syndrome. BMJ 2005;331:829–830.
3.
Bonkowsky JL, Filloux FM: Extrapontine myelinolysis in a pediatric case of diabetic ketoacidosis and cerebral edema. J Child Neurol 2003;18:144–147.
4.
Brito AR, Vasconcelos MM, Cruz Júnior LC, Oliveira ME, Azevendo AR, Rocha LG, Mendonça PC: Central pontine and extrapontine myelinolysis: report of a case with a tragic outcome. J Pediatr (Rio J) 2006;82:157–160.
5.
Decaux G: Treatment of severe hyponatremia (<120 mEq/l) (in French). Rev Med Brux 2001;22:413–419.
6.
Hoorn EJ, Zietse R: Hyponatremia revisited: translating physiology to practice. Nephron Physiol 2008;108:46–59.
7.
Agrawal V, Agarwal M, Joshi SR, Ghosh AK: Hyponatremia and hypernatremia: disorders of water balance. J Assoc Physicians India 2008;56:956–964.
8.
Huq S, Wong M, Chan H, Crimmins D: Osmotic demyelination syndromes: central and extrapontine myelinolysis. J Clin Neurosci 2007;14:684–688.
9.
Kleinschmidt-DeMasters BK, Rojiani AM, Filley CM: Central and extrapontine myelinolysis: then and now. J Neuropathol Exp Neurol 2006;65:1–11.
10.
Lampl C, Yazdi K: Central pontine myelinolysis. Eur Neurol 2002;47:3–10.
11.
Pradhan S, Jha R, Singh MN, Gupta S, Phadke RV, Kher V: Central pontine myelinolysis following ‘slow’ correction of hyponatremia. Clin Neurol Neurosurg 1995;97:340–343.
12.
Kumar S, Fowler M, Gonzalez-Toledo E, Jaffe SL: Central pontine myelinolysis, an update. Neurol Res 2006;28:360–366.
13.
Pearce JM: Central pontine myelinolysis. Eur Neurol 2009;61:59–62.
14.
Pirzada NA, Ali II: Central pontine myelinolysis. Mayo Clin Proc 2001;76:559–562.
15.
Boon AP, Carey MP, Adams DH, Buckels J, McMaster P: Central pontine myelinolysis in liver transplantation. J Clin Pathol 1991;44:909–914.
16.
de Morais BS, Carneiro FS, Araújo Rde M, Araújo GF, de Oliveira RB: Central pontine myelinolysis after liver transplantation: is sodium the only villain? Case report (in English, Portuguese). Rev Bras Anestesiol 2009;59:344–349.
17.
Hall WA, Martinez AJ: Neuropathology of pediatric liver transplantation. Pediatr Neurosci 1989;15:269–275.
18.
Kabeer MH, Filo RS, Milgrom ML, Pescovitz MD, Leapman SB, Lumeng L, et al: Central pontine myelinolysis following orthotopic liver transplant: association with cyclosporine toxicity. Postgrad Med J 1995;71:239–241.
19.
Lee EM, Kang JK, Yun SC, Kim KH, Kim SJ, Hwang KS, et al: Risk factors for central pontine and extrapontine myelinolysis following orthotopic liver transplantation. Eur Neurol 2009;62:362–368.
20.
Martinez AJ, Estol C, Faris AA: Neurologic complications of liver transplantation. Neurol Clin 1988;6:327–348.
21.
Senzolo M, Ferronato C, Burra P: Neurologic complications after solid organ transplantation. Transpl Int 2009;22:269–278.
22.
Yu J, Zheng SS, Liang TB, Shen Y, Wang WL, Ke QH: Possible causes of central pontine myelinolysis after liver transplantation. World J Gastroenterol 2004;10:2540–2543.
23.
Zhang ZW, Kang Y, Deng LJ, Luo CX, Zhou Y, Xue XS, et al: Therapy of central pontine myelinolysis following living donor liver transplantation: report of three cases. World J Gastroenterol 2009;15:3960–3963.
24.
Choe WJ, Cho BK, Kim IO, Shin HY, Wang KC: Extrapontine myelinolysis caused by electrolyte imbalance during the management of suprasellar germ cell tumors: report of two cases. Childs Nerv Syst 1998;14:155–158.
25.
Cuvellier JC, Soto Ares G, de Sèze C, Santos C, Cuisset JM, Dhelleemmes P, et al: Radiology case of the month: extrapontine myelinolysis (in French). Arch Pediatr 2000;7:75–77.
26.
Di Rocco F, Caldarelli M, Di Rocco C: Extrapontine reversible myelinolysis in a child operated on for craniopharyngioma. Pediatr Neurosurg 2001;34:166–167.
27.
Kawahara I, Tokunaga Y, Ishizaka S, Yagi N: Reversible clinical and magnetic resonance imaging of central pontine myelinolysis following surgery for craniopharyngioma: serial magnetic resonance imaging studies. Neurol Med Chir (Tokyo) 2009;49:120–123.
28.
Kepes JJ, Reece CA, Oxley DK: Central pontine myelinolysis in a 7-year-old boy. J Neurol Neurosurg Psychiatry 1965;28:39–47.
29.
Matsuoka T, Miyoshi K, Saka K, Hayashi S, Kageyama N: Central pontine myelinolysis: a report of three cases. Acta Neuropathol 1965;5:117–132.
30.
Niehaus L, Kulozik A, Lehmann R: Reversible central pontine and extrapontine myelinolysis in a 16-year-old girl. Childs Nerv Syst 2001;17:294–296.
31.
Tsutsumi S, Yasumoto Y, Ito M: Central pontine and extrapontine myelinolysis in an infant associated with the treatment of craniopharyngioma: case report. Neurol Med Chir (Tokyo) 2008;48:351–354.
32.
Chua GC, Sitoh YY, Lim CC, Chua HC, Ng PY: MRI findings in osmotic myelinolysis. Clin Radiol 2002;57:800–806.
33.
Toumba M, Stanhope R: Morbidity and mortality associated with vasopressin analogue treatment. J Pediatr Endocrinol Metab 2006;19:197–201.
34.
Gutenstein M: Osmotic myelinolysis syndrome after treatment of severe deamino arginine vasopressin-associated hyponatraemia: pitfalls in emergency medicine. Emerg Med Australas 2007;19:68–70.
35.
Maghnie M, Genovese E, Lundin S, Bonetti F, Arico M: Iatrogenic [corrected] extrapontine myelinolysis in central diabetes insipidus: are cyclosporine and 1-desamino-8-D-arginine vasopressin harmful in association? J Clin Endocrinol Metab 1997;82:1749–1751.
36.
Lasheen I, Doi SA, Al-Shoumer KA: Glucocorticoid replacement in panhypopituitarism complicated by myelinolysis. Med Princ Pract 2005;14:115–117.
37.
Ranger A, Levin S, Salvadori M, Fraser D: Central pontine and extrapontine myelinolysis in the pediatric population: a detailed review and analysis of the literature. 2010, unpubl.
38.
van Wissen K, Breton C: Perioperative influences on fluid distribution. Medsurg Nurs 2004;13:304–311.
39.
Kennedy JM, Jiji AM: Effects of surgery on the pharmacokinetic parameters of drugs. Clin Pharmacokinet 1998;35:293–312.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.